Format

Send to

Choose Destination
Gynecol Oncol. 2017 Jul;146(1):129-136. doi: 10.1016/j.ygyno.2017.04.005. Epub 2017 Apr 18.

Autoantibody biomarkers for the detection of serous ovarian cancer.

Author information

1
Virginia G. Piper Center for Personal Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA.
2
Department of Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, USA.
3
Virginia G. Piper Center for Personal Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA. Electronic address: Karen.Anderson.1@asu.edu.

Abstract

Objective The purpose of this study was to identify a panel of novel serum tumor antigen-associated autoantibody (TAAb) biomarkers for the diagnosis of high-grade serous ovarian cancer.

METHODS:

To detect TAAb we probed high-density programmable protein microarrays (NAPPA) containing 10,247 antigens with sera from patients with serous ovarian cancer (n=30 cases/30 healthy controls) and measured bound IgG. We identified 735 promising tumor antigens and evaluated these with an independent set of serous ovarian cancer sera (n=30 cases/30 benign disease controls/30 healthy controls). Thirty-nine potential tumor autoantigens were identified and evaluated using an orthogonal programmable ELISA platform against a total of 153 sera samples (n=63 cases/30 benign disease controls/60 healthy controls). Sensitivities at 95% specificity were calculated and a classifier for the detection of high-grade serous ovarian cancer was constructed.

RESULTS:

We identified 11-TAAbs (ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3) that distinguished high-grade serous ovarian cancer cases from healthy controls with a combined 45% sensitivity at 98% specificity.

CONCLUSION:

These are potential circulating biomarkers for the detection of serous ovarian cancer, and warrant confirmation in larger clinical cohorts.

KEYWORDS:

Autoantibody; Biomarker; Diagnostics; Ovarian cancer; Proteomics

PMID:
28427776
PMCID:
PMC5519143
DOI:
10.1016/j.ygyno.2017.04.005
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center